Scientific reports
Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in a liver metastatic model of pancreatic ductal adenocarcinoma.
Krisztina Andrea Szigeti, Marcell Baranyi, Sára Surguta, Balázs Hegedűs, Violetta Piurkó, József Tóvári, József Tímár
Published: 202610.1038/s41598-025-34204-y
Abstract
MRTX1133 is a first-in-class KRAS G12D inhibitor being in phase I/II clinical trials. KRAS is the most frequently mutated oncogene in pancreatic ductal adenocarcinoma (PDAC), with a predominance of the G12D variant. PDAC is a highly lethal cancer typ…
Preview only. Read the full abstract at the source